Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has issued an announcement.
JW Therapeutics announced that the National Medical Products Administration of China has accepted its post-marketing supplementary application for Carteyva®, which now uses an in-house produced lentiviral vector. This development is significant as it ensures a stable supply and reduces costs, enhancing the commercial value of Carteyva® and strengthening JW Therapeutics’ position in the competitive cell therapy market.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is an independent and innovative biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products. The company is known for its CAR-T cell immunotherapy product, Carteyva®, which is approved for multiple oncology indications in China.
Average Trading Volume: 4,988,280
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.94B
Learn more about 2126 stock on TipRanks’ Stock Analysis page.